Neurocrine Biosciences
NBIX
#1404
Rank
HK$125.23 B
Marketcap
HK$1,245
Share price
-1.41%
Change (1 day)
34.34%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2026 (TTM): HK$6.23 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are HK$3.10 Billion. In 2025 the company made an earning of HK$4.98 Billion, an increase over its 2024 earnings that were of HK$4.79 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) HK$6.23 B25.12%
2025 HK$4.98 B3.9%
2024 HK$4.79 B96.41%
2023 HK$2.44 B41.13%
2022 HK$1.73 B73.74%
2021 HK$0.99 B-8.82%
2020 HK$1.09 B77.78%
2019 HK$0.61 B49.83%
2018 HK$0.41 B-142.57%
2017 -HK$0.97 Billion-14.73%
2016 -HK$1.13 Billion53.15%
2015 -HK$0.74 Billion46.25%
2014 -HK$0.51 Billion29.66%
2013 -HK$0.39 Billion-3530.8%
2012 HK$11.33 M-95.73%
2011 HK$0.26 B
2009 -HK$0.38 Billion-45.38%
2008 -HK$0.69 Billion-58.87%
2007 -HK$1.67 Billion87.3%
2006 -HK$0.89 Billion351.97%
2005 -HK$0.2 Billion-52.09%
2004 -HK$0.41 Billion-10.98%
2003 -HK$0.47 Billion
2001 -HK$0.35 Billion
1999 -HK$0.16 Billion108.32%
1998 -HK$74.4 Million
1996 HK$22.7 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
HK$82.93 B 1,225.86%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
HK$51.65 B 725.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
HK$243.73 B 3,796.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
HK$0.65 B-89.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-HK$0.33 Billion-105.23%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
HK$0.75 B-88.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-HK$37.55 Million-100.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
HK$13.27 B 112.21%๐Ÿ‡ฌ๐Ÿ‡ง UK